Potential involvement of tyrosine phosphatase and calpain-related pathways in opioid withdrawal syndrome in mice

Behavioural Pharmacology

Volumn 23, Issue 3, 2012, Pages 302-309

  Rehni, Ashish K ^a   Singh, Nirmal ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Calpain; Morphine dependence; Mouse; Tyrosine phosphatase; Withdrawal syndrome

Indexed keywords

CALPAIN; MORPHINE; NALOXONE; PROTEIN TYROSINE PHOSPHATASE; VANADATE SODIUM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; JUMPING; LICKING; MALE; MOUSE; NONHUMAN; REARING; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; CALPAIN; FEMALE; MALE; MICE; MORPHINE; MORPHINE DEPENDENCE; MOTOR ACTIVITY; NALOXONE; PROTEIN TYROSINE PHOSPHATASES; STEREOTYPED BEHAVIOR; SUBSTANCE WITHDRAWAL SYNDROME; VANADATES;

EID: 84860745125     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32835398ec     Document Type: Article

References (60)

1. Akil H, Lewis JW (1987). Neurotransmitters and Pain Control, vol. 9: Pain and Headache. Basil: Karger. pp. 129-159.
2. Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, Godzik A, et al. (2004). Protein tyrosine phosphatases in the human genome. Cell 117:699-711.
3. Ariyoshi H, Oda A, Salzman EW (1995). Participation of calpain in proteintyrosine phosphorylation and dephosphorylation in human blood platelets. Arterioscler Thromb Vasc Biol 15:511-514.
4. Avidor-Reiss T, Nevo I, Levy R, Pfeuffer T, Vogel Z (1996). Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma. J Biol Chem 271:21309-21315.
5. Avidor-Reiss T, Nevo I, Saya D, Bayewitch M, Vogel Z (1997). Opiate-induced adenylyl cyclase superactivation is isozyme-specific. J Biol Chem 272: 5040-5047.
6. Barrett P, Choi WS, Morris M, Morgan P (2000). A role for tyrosine phosphorylation in the regulation and sensitization of adenylate cyclase by melatonin. FASEB J 14:1619-1628.
7. Chakrabarti S, Oppermann M, Gintzler AR (2001). Chronic morphine induces the concomitant phosphorylation and altered association of multiple signaling proteins: a novel mechanism for modulating cell signaling. Proc Natl Acad Sci USA 98:4209-4214.
8. D'Amour FE, Smith DL (1941). A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74.
9. Drdla R, Gassner M, Gingl E, Sandkü hler J (2009). Induction of synaptic longterm potentiation after opioid withdrawal. Science 325:207-210.
10. Esmaeili-Mahani S, Fathi Y, Motamedi F, Hosseinpanah F, Ahmadiani A (2008). L-type calcium channel blockade attenuates morphine withdrawal: in vivo interaction between L-type calcium channels and corticosterone. Horm Behav 53:351-357.
11. Falls WA, Kelsey JE (1989). Procedures that produce context-specific tolerance to morphine in rats also produce context-specific withdrawal. Behav Neurosci 103:842-849.
12. Fan T, Varghese G, Nguyen T, Tse R, O'Dowd BF, George SR (2005). A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J Biol Chem 280:38478-38488.
13. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, et al. (2000). Oligomerization of mu-and delta-opioid receptors. generation of novel functional properties. J Biol Chem 275:26128-26135.
14. Georgescu D, Zachariou V, Barrot M, Mieda M,Willie JT, Eisch AJ, et al. (2003). Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci 23:3106-3111.
15. Gil-Henn H, Volohonsky G, Elson A (2001). Regulation of protein-tyrosine phosphatases a and E by calpain-mediated proteolytic cleavage. J Biol Chem 276:31772-31779.
16. Glick SD, Morihisa JM (1976). Changes in sensitivity of morphine-induced circling behaviour after chronic treatment and persistence after withdrawal in rats. Nature 260:159-161.
17. Goll DE, Thompson VF, Li H,Wei W, Cong J (2003). The calpain system. Physiol Rev 83:731-801.
18. Hamdy MM, Noda Y, Miyazaki M, Mamiya T, Nozaki A, Nitta A, et al. (2004). Molecular mechanisms in dizocilpine-induced attenuation of development of morphine dependence: an association with cortical Ca2 +calmodulindependent signal cascade. Behav Brain Res 152:263-270.
19. Hardman JG, Limbird LE, Gilman AG (2001). Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw Hill. pp. 631-634.
20. Herradó n G, Ezquerra L, Gramage E, Alguacil LF (2009). Targeting the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta signaling pathway to limit neurotoxicity induced by drug abuse. Mini Rev Med Chem 9:440-447.
21. Inoue M, Mishina M, Ueda H (2003). Locus specific rescue of GluR-1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence. J Neurosci 23:6529-6536.
22. Ishiguro H, Gong JP, Hall FS, Arinami T, Uhl GR (2008). Association of PTPRB gene polymorphism with drug addiction. Am J Med Genet B Neuropsychiatr Genet 147:1167-1172.
23. Koob GF, Bloom FE (1988). Cellular and molecular mechanisms of drug dependence. Science 242:715-723.
24. Krantz MJ, Mehler PS (2004). Treating opioid dependence growing implications for primary care. Arch Intern Med 164:277-288.
25. Law PY, Hom DS, Loh HH (1982). Loss of opiate receptor activity in neuroblastoma X glioma NG108-15 hybrid cells after chronic opiate treatment. A multiple-step process. Mol Pharmacol 22:1-4.
26. Law PY, Wong YH, Loh HH (2000). Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 40:389-430.
27. Li X, Schwacha MG, Chaudry IH, Choudhry MA (2008). Inhibition of protein tyrosine phosphatases prevents mesenteric lymph node T-cell suppression following alcohol intoxication and burn injury. J Burn Care Res 29:519-530.
28. Liu JG, Anand KJ (2001). Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. Brain Res Brain Res Rev 38:1-19.
29. Liu X, Harriman JF, Schnellmann RG (2002). Cytoprotective properties of novel nonpeptide calpain inhibitors in renal cells. J Pharmacol Exp Ther 302:88-94.
30. Liu Z, Zheng JF, Yang LQ, Yi L, Hu B (2007). Effects of sinomenine on NO/nNOS system in cerebellum and spinal cord of morphine-dependent and withdrawal mice. Sheng Li Xue Bao 59:285-292.
31. Marshall J, Graham-Smith DG (1971). Evidence against a role of brain 5-hydroxytryptamine in the development of physical dependence upon morphine in mice. J Pharmacol Exp Ther 173:634-641.
32. McClung CA, Nestler EJ, Zachariou V (2005). Regulation of gene expression by chronic morphine and morphine withdrawal in the locus coeruleus and ventral tegmental area. J Neurosci 25:6005-6015.
33. McLauchlan CC, Hooker JD, Jones MA, Dymon Z, Backhus EA, Greiner BA, et al. (2010). Inhibition of acid, alkaline, and tyrosine (PTP1B) phosphatases by novel vanadium complexes. J Inorg Biochem 104:274-281.
34. Meng G,Wu N, Zhang C, Su RB, Lu XQ, Liu Y, et al. (2008). Analgesic activity of ZC88, a novel N-type voltage-dependent calcium channel blocker, and its modulation of morphine analgesia, tolerance and dependence. Eur J Pharmacol 586:130-138.
35. Mostany R, D{az A, Valdizan EM, Rodr{guez-Munoz M, Garzon J, Hurle MA (2008). Supersensitivity to m-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits. Neuropharmacology 54:989-997.
36. Nestler EJ (2004). Historical review: molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol Sci 25:210-218.
37. O'Connor TJ, Bjorge JD, Cheng HC, Wang JH, Fujita DJ (1995). Mechanism of c-SRC activation in human melanocytes: elevated level of protein tyrosine phosphatase activity directed against the carboxy-terminal regulatory tyrosine. Cell Growth Differ 6:123-130.
38. Patkina NA, Zvartau EE (1978). Rat behavior in an 'open field' when chronically administered morphine. Farmakol Toksikol 41:537-541.
39. Paul S, Lombroso PJ (2003). Receptor and nonreceptor protein tyrosine phosphatases in the nervous system. Cell Mol Life Sci 60:2465-2482.
40. Pineyro G, Archer-Lahlou E (2007). Ligand-specific receptor states: implications for opiate receptor signalling and regulation. Cell Signal 19:8-19.
41. Ragab A, Bodin S, Viala C, Chap H, Payrastre B, Ragab-Thomas J (2003). The tyrosine phosphatase 1B regulates linker for activation of T-cell phosphorylation and platelet aggregation upon FcgRIIa cross-linking. J Biol Chem 278:40923-40932.
42. Reddy DS, Kulkarni SK (1998). Possible role of nitric oxide in the nootropic and antiamnesic effects of neurosteroids on aging and dizocilpine-induced learning impairment. Brain Res 799:215-229.
43. Rehni AK, Singh N (2011). Modulation of src-kinase attenuates naloxoneprecipitated opioid withdrawal syndrome in mice. Behav Pharmacol 22: 182-190.
44. Rehni AK, Bhateja P, Singh TG, Singh N (2008a). Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome. Behav Pharmacol 19: 265-269.
45. Rehni AK, Singh I, Singh N, Bansal N, Bansal S, Kumar M (2008b). Pharmacological modulation of leukotriene D(4) attenuates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome. Eur J Pharmacol 598:51-56.
46. Sato-Kusubata K, Yajima Y, Kawashima S (2000). Persistent activation of Gsalpha through limited proteolysis by calpain. Biochem J 347:733-740.
47. Sharma KS, Klee WA, Nirenberg M (1977). Opiate-dependent modulation of adenylate cyclase. Proc Natl Acad Sci USA 74:3365-3369.
48. Shaw-Lutchman TZ, Barrot M, Wallace T, Gilden L, Zachariou V, Impey S, et al. (2002). Regional and cellular mapping of cAMP response element-mediated transcription during naltrexone precipitated morphine withdrawal. J Neurosci 22:3663-3672.
49. Sugano M, Tsuchida K, Makino N (2004). A protein tyrosine phosphatase inhibitor accelerates angiogenesis in a rat model of hindlimb ischemia. J Cardiovasc Pharmacol 44:460-465.
50. Sweitzer SM,Wong SM, Tjolsen A, Allen CP, Mochly-Rosen D, Kendig JJ (2004). Exaggerated nociceptive responses on morphine withdrawal: roles of protein kinase C epsilon and gamma. Pain 110:281-289.
51. Trujillo KA, Akil H (1991). Inhibition of morphine tolerance and dependence by NMDA receptor antagonist MK-801. Science 251:85-87.
52. Trujillo KA, Akil H (1995). Excitatory amino acids and drugs of abuse: a role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence. Drug Alcohol Depend 38:139-154.
53. Van Ree JM, Gerrits MAFM, Vanderschuren LJMJ (1999). Opioids, reward and addiction: an encounter of biology, psychology, and medicine. Pharmacol Rev 51:341-396.
54. Way EL, Loh HH, Shen FH (1969). Simultaneous quantitative assessment of morphine tolerance and physical dependence. J Pharmacol Exp Ther 167:1-8.
55. Williams JT, Christie MJ, Manzoni O (2001). Cellular and Synaptic Adaptations Mediating Opioid Dependence. Physiol Rev 81:299-343.
56. World Health Organisation (2003). Management of Substance Dependence, http://www.who.int/substance-abuse.
57. Zadran S, Bi X, Baudry M (2010). Regulation of calpain-2 in neurons: implications for synaptic plasticity. Mol Neurobiol 42:143-150.
58. Zang M, Shen Q, Sun Y,Wang Q, Liu J (2000). Mechanisms of opioid receptorinduced elevation in intracellular calcium by confocal laser scanning microscopy. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 22:254-258.
59. Zhang L, Zhao H, Qiu Y, Loh HH, Law PY (2009). Src phosphorylation of m-receptor is responsible for the receptor switching from an inhibitory to a stimulatory signal. J Biol Chem 284:1990-2000.
60. Zhou D, Collins CA, Wu P, Brown EJ (2010). Protein tyrosine phosphatase SHP-1 positively regulates TLR-induced IL-12p40 production in macrophages through inhibition of phosphatidylinositol 3-kinase. J Leukoc Biol 87: 845-855.